Skip to main
BOLD
BOLD logo

BOLD Stock Forecast & Price Target

BOLD Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Boundless Bio Inc. is strategically positioned in the oncology market by targeting a critical area of unmet need with its pioneering approach to address oncogene-amplified tumors through the use of extrachromosomal DNA (ecDNA). The potential of its lead candidate, BBI-355, as a toxicity-mitigated oral selective inhibitor of CHK1 supports a promising framework for enhanced efficacy, especially when leveraged in combination therapies. Additionally, while current valuations do not account for supplementary technologies, their successful development represents a potential upside, indicating significant long-term growth prospects for the company.

Bears say

Boundless Bio Inc faces significant challenges that contribute to a negative outlook on its stock. Key risks include potential delays in the clinical development of BBI-355, particularly in light of negative clinical data regarding its therapeutic window, and the possibility of failing to achieve regulatory approval. Additionally, slower-than-anticipated commercial uptake for BBI-355, combined with potential setbacks in other pipeline programs and the risk of medium- to long-term dilution, further complicate the company's financial prospects.

BOLD has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boundless Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boundless Bio Inc (BOLD) Forecast

Analysts have given BOLD a Buy based on their latest research and market trends.

According to 2 analysts, BOLD has a Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boundless Bio Inc (BOLD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.